HYBRID EVENT: Join us in person in Singapore or attend virtually from anywhere.

3rd Edition of International Cancer & Immuno-Oncology Conference

March 15-17, 2027 | Singapore
March 15-17, 2027 | Singapore

Thymus Cancer

Thymus Cancer

Thymus cancer, a rare malignancy originating in the thymus gland, presents unique challenges in cancer research due to its rarity and complex biology. As a critical component of the immune system, the thymus plays a crucial role in T-cell maturation and immune function. Current research focuses on understanding the genetic and molecular mechanisms underlying thymus cancer development, as well as identifying potential therapeutic targets. Immunotherapy, particularly checkpoint inhibitors, shows promise in treating thymic malignancies by enhancing the body's immune response against cancer cells. Additionally, advancements in precision medicine and targeted therapies offer hope for improved outcomes and personalized treatment approaches. Collaborative efforts among researchers, clinicians, and patients are essential to accelerate progress in thymus cancer research and develop more effective therapies for this challenging disease.

Committee Members
Committee Member - Jianhua Luo

Jianhua Luo

University of Pittsburgh School of Medicine, United States
Committee Member - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Committee Member - Yan Leyfman

Yan Leyfman

NYP- Meyer Cancer Center, United States

Submit your abstract Today

YouTube
WhatsAppWhatsApp